What You Should Know
– ConcertAI and Foundation Medicine have announced a major strategic collaboration to integrate their massive data assets, creating a dataset of nearly half a million patients.
– By pairing Foundation Medicine’s de-identified multimodal genomic testing data with ConcertAI’s high-quality clinical records, the partnership provides life science researchers with the market’s most comprehensive view of the cancer patient journey—from pre-diagnosis to long-term outcomes.
The Multi-Modal Edge: Genomics, Imaging, and Real-World Evidence
As oncology drug programs face tightening budgets and increasing trial complexity, the industry is shifting toward “Data Activation” to reduce early-stage guesswork. The combined dataset goes beyond simple sequencing to offer a truly multimodal view of disease.
- Comprehensive Genomics: Includes FDA-approved diagnostic signatures and difficult-to-detect alterations, such as MTAP loss, which are often missed by standard next-generation sequencing.
- Visual Intelligence: The dataset integrates whole-slide imaging, gene expression data, and immunohistochemistry (IHC) results.
- Clinical Depth: ConcertAI provides one of the industry’s most diverse clinical datasets, spanning socioeconomic, ethnic, and geographic (rural vs. urban) boundaries.
Accelerating the “Test-to-Treatment” Pipeline
The primary goal of the collaboration is to help biopharmaceutical teams set clearer research plans and speed up drug pipelines. By capturing the “full journey,” researchers can better understand how cancers behave in real-world settings and how patients respond to specific targeted therapies over time.
“Drug developers are increasingly pushed to accelerate their research pipelines but require more robust insights into both early genomic signals and patient outcomes to make this a reality,” said Eron Kelly, CEO of ConcertAI. “By combining the largest and deepest set of clinical data with genomic insights, including whole slide imaging, we can help teams set a clearer plan and speed up their projects. Our collaboration with Foundation Medicine complements our full suite of partnerships aimed at advancing the development of vital therapies.”
